We are excited to share that Medasense’s technology was chosen to be highlighted in the British Journal of Anaesthesia (BJA) review article “Digital innovations and emerging technologies for enhanced recovery programmes”.

We are pleased to share with you the exciting news that Medasense has received AMAR approval to sell our pain (Nociception) monitoring system in Israel!
Israeli anesthesiologists are now able to join their European colleagues, who are already using our technology , to optimize and personalize the intraoperative analgesic administration.

This is a significant milestone for Medasense. We are very proud to enter our home market, where our technology was developed!

Medasense featured in Innovations in Pharmaceutical Technology publication.
Read our article written by CEO, Galit Zuckerman-Stark, to learn how an objective approach could help healthcare professionals better assess pain.

Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD200™. This new technology is now available to help physicians objectively assess a patient’s pain in critical care situations, where